- HER2 negative
- ER positive
- HER2 positive
- PR positive
- ER negative
- PD-L1 positive
- PR negative
- BRAF positive
- KRAS positive
- BRCA1 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- Adjuvant Therapy (except reconstruction)
- Anthracycline
- At least one prior tumor-directed therapy
- Biologic Anti-Neoplastic Agent
- Cancer-Directed Surgery
- Carboplatin
- Chemotherapy
- Endocrine Therapy
- Endocrine Therapy (prescription with intent to initiate within 6 weeks after registration)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
602 trials
Trials Without a Placebo
Dayton, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Efficacy & Safety Awards
Pivotal Trial
Dayton, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether ianalumab is an effective and safe treatment for patients with active Sjögren's syndrome.
Efficacy & Safety Awards
Pivotal Trial
Dayton, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Dayton, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Efficacy & Safety Awards
Pivotal Trial
Dayton, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Dayton, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying a drug called frexalimab to see if it can help delay disability progression in people with a certain type of multiple sclerosis. The study will last between 27 to
Efficacy & Safety Awards
Pivotal Trial
Dayton, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Dayton, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.
Efficacy & Safety Awards
Pivotal Trial
Dayton, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Get notified when new COPD trials are postedWe'll send you an email whenever new trials are posted
Dayton, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether CHF 5993 is more effective than CHF 1535 at improving lung function, reducing exacerbations of COPD, and improving other clinical outcomes.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Dayton, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to see if a new drug can delay memory or thinking problems in Alzheimer's disease compared to a placebo. Participants will be in the study for up to 255 weeks, including treatment and
Efficacy & Safety Awards
Pivotal Trial
Dayton, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Dayton, OH (<10 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called BMS-986446 in people with early Alzheimer's disease. The medication is designed to target harmful proteins in the brain to slow down the disease. Researchers are checking if it works well and is safe for patients.
SummaryThis trial is being conducted to assess the effectiveness and safety of a drug called LB-102 in adult patients with schizophrenia experiencing worsening symptoms. The study will compare the effects of LB-102 to a placebo
Dayton, OH (<10 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.
SummaryThis trial is testing a new drug called LX9211 to see if it can reduce nerve pain in people with diabetes. The drug works by blocking pain signals in the nerves. Researchers want to find out if it is more effective than other treatments. A similar drug was previously tested for similar conditions but its development was halted due to safety concerns.
Dayton, OH (<10 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether cabozantinib alone or with nivolumab is better than other treatments for patients with a type of lung cancer called non-squamous non-small cell lung cancer. Cabozantinib stops cancer cells from growing, while nivolumab helps the immune system fight the cancer. The goal is to see if these treatments can help patients live longer without their cancer getting worse.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Meningioma trials are postedWe'll send you an email whenever new trials are posted
Dayton, OH (<10 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Dayton, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares giving standard therapy after surgery to giving standard therapy before and after surgery in patients with a specific type of lung cancer that can be removed by surgery. The goal is to determine which approach is
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…31